Croda’s Incromega™ TG3322 fish oil concentrate has recently been featured in a study undertaken at The University of Copenhagen. The study explored the reduction in the risk of asthma developing in children after birth, with those mothers taking the fish oil supplement during pregnancy. The study was undertaken at Copenhagen University, within their clinical research unit for pediatric asthma research. The fish oil concentrate used in the study was Croda’s Incromega™ TG3322.
Incromega™ TG3322 is a marine oil concentrate rich in Omega 3 polyunsaturated fatty acids (PUFAs), with the specific key components being eicosapentaenoic acid and docosahexaenoic acid (EPA and DHA). It is PhEur and GOED monograph compliant and supplied in a highly bioavailable triglyceride form.
The study found that children born to mothers who had taken fish oil capsules during their last trimester of pregnancy were proven to be around 31% less likely to develop asthma by the age of 3, compared to those whose mothers who had taken placebos. The benefits mostly observed were amongst children with mothers who initially had low blood levels of EPA and DHA. It had been suggested that the findings may prompt precision dosing of fish oil, but researchers suggest further studies to be undertaken for dosing and timing is required.
Gerry Purnell, Sales Director - Nutritional, Croda Europe commented ‘Croda have supported and collaborated with numerous universities on a wide range of clinical research studies demonstrating the efficacy of Omega 3 in supporting health, treating and preventing disease. The efficacy and safety of our Incromega™ EPA and DHA concentrates have been demonstrated consistently in human clinical trials and we will endeavour to support current and future research into the beneficial effects of Omega 3 fatty acids. Croda has thirty years heritage in manufacturing fish oil concentrates for nutritional and pharmaceutical application guaranteeing very high levels of purity and overall quality standards.’